JPWO2020249002A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020249002A5 JPWO2020249002A5 JP2021572442A JP2021572442A JPWO2020249002A5 JP WO2020249002 A5 JPWO2020249002 A5 JP WO2020249002A5 JP 2021572442 A JP2021572442 A JP 2021572442A JP 2021572442 A JP2021572442 A JP 2021572442A JP WO2020249002 A5 JPWO2020249002 A5 JP WO2020249002A5
- Authority
- JP
- Japan
- Prior art keywords
- oral capsule
- capsule composition
- zanubrutinib
- adhesive
- further optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025106604A JP2025123534A (ja) | 2019-06-10 | 2025-06-24 | 経口カプセルおよびその調製方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/090543 | 2019-06-10 | ||
| CN2019090543 | 2019-06-10 | ||
| PCT/CN2020/095353 WO2020249002A1 (zh) | 2019-06-10 | 2020-06-10 | 口服胶囊剂及其制备方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106604A Division JP2025123534A (ja) | 2019-06-10 | 2025-06-24 | 経口カプセルおよびその調製方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022538215A JP2022538215A (ja) | 2022-09-01 |
| JPWO2020249002A5 true JPWO2020249002A5 (enExample) | 2023-06-20 |
Family
ID=73780902
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572442A Withdrawn JP2022538215A (ja) | 2019-06-10 | 2020-06-10 | 経口カプセルおよびその調製方法 |
| JP2025106604A Pending JP2025123534A (ja) | 2019-06-10 | 2025-06-24 | 経口カプセルおよびその調製方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106604A Pending JP2025123534A (ja) | 2019-06-10 | 2025-06-24 | 経口カプセルおよびその調製方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20220241285A1 (enExample) |
| EP (1) | EP3981400A4 (enExample) |
| JP (2) | JP2022538215A (enExample) |
| CN (1) | CN113950327A (enExample) |
| TW (1) | TW202112369A (enExample) |
| WO (1) | WO2020249002A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗ｐｄ−１抗体並びにその治療及び診断のための使用 |
| KR102003754B1 (ko) | 2014-07-03 | 2019-07-25 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| KR102604975B1 (ko) | 2016-08-16 | 2023-11-24 | 베이진 스위찰랜드 게엠베하 | (s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로 [1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도 |
| EP3500299B1 (en) | 2016-08-19 | 2023-12-13 | BeiGene Switzerland GmbH | Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer |
| KR102757960B1 (ko) | 2017-06-26 | 2025-01-22 | 베이진 엘티디 | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| US20220249491A1 (en) | 2019-06-10 | 2022-08-11 | Beigene Switzerland Gmbh | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor |
| CN115212115A (zh) * | 2021-09-27 | 2022-10-21 | 百济神州(苏州)生物科技有限公司 | 泽布替尼的鼻饲给药 |
| CN119699478B (zh) * | 2024-12-24 | 2025-12-12 | 衡睿(广东)生物科技有限公司 | 一种高油脂含量的胶囊制剂及其制备方法 |
| CN119818691B (zh) * | 2025-03-18 | 2025-08-05 | 宁波美诺华天康药业有限公司 | 一种含有伊布替尼的药物组合物及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201506764WA (en) * | 2013-04-25 | 2015-09-29 | Beigene Ltd | Fused heterocyclic compounds as protein kinase inhibitors |
| US9717745B2 (en) * | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| KR102604975B1 (ko) * | 2016-08-16 | 2023-11-24 | 베이진 스위찰랜드 게엠베하 | (s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로 [1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도 |
| MA52090A (fr) * | 2018-03-21 | 2021-04-21 | Mei Pharma Inc | Polythérapie |
| US10688050B1 (en) * | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
-
2020
- 2020-06-10 WO PCT/CN2020/095353 patent/WO2020249002A1/zh not_active Ceased
- 2020-06-10 JP JP2021572442A patent/JP2022538215A/ja not_active Withdrawn
- 2020-06-10 US US17/617,531 patent/US20220241285A1/en active Pending
- 2020-06-10 CN CN202080043268.7A patent/CN113950327A/zh active Pending
- 2020-06-10 EP EP20822606.8A patent/EP3981400A4/en active Pending
- 2020-06-10 TW TW109119516A patent/TW202112369A/zh unknown
-
2023
- 2023-01-20 US US18/099,319 patent/US20230149411A1/en active Pending
-
2025
- 2025-06-24 JP JP2025106604A patent/JP2025123534A/ja active Pending